Koss Olinger Consulting LLC Sells 6,165 Shares of CVS Health Co. (NYSE:CVS)

Koss Olinger Consulting LLC reduced its stake in CVS Health Co. (NYSE:CVS - Free Report) by 17.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,719 shares of the pharmacy operator's stock after selling 6,165 shares during the period. Koss Olinger Consulting LLC's holdings in CVS Health were worth $1,289,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Davis Selected Advisers raised its position in shares of CVS Health by 2,998.1% in the 4th quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator's stock valued at $511,115,000 after buying an additional 11,018,438 shares in the last quarter. Pzena Investment Management LLC increased its stake in CVS Health by 49.3% in the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock valued at $880,319,000 after acquiring an additional 6,475,271 shares during the last quarter. Hotchkis & Wiley Capital Management LLC raised its position in CVS Health by 34.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 11,897,034 shares of the pharmacy operator's stock valued at $748,085,000 after purchasing an additional 3,071,613 shares in the last quarter. Raymond James Financial Inc. bought a new stake in CVS Health during the fourth quarter worth $116,033,000. Finally, ARGA Investment Management LP increased its stake in shares of CVS Health by 7,567.7% in the 4th quarter. ARGA Investment Management LP now owns 2,402,901 shares of the pharmacy operator's stock valued at $107,866,000 after purchasing an additional 2,371,563 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.

Remove Ads

CVS Health Stock Down 2.1 %

Shares of CVS stock traded down $1.42 on Friday, reaching $67.22. 18,107,103 shares of the company were exchanged, compared to its average volume of 11,100,536. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The company has a 50-day moving average of $60.60 and a 200-day moving average of $57.35. The company has a market cap of $84.75 billion, a price-to-earnings ratio of 18.37, a PEG ratio of 0.98 and a beta of 0.54. CVS Health Co. has a one year low of $43.56 and a one year high of $80.75.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.96%. The ex-dividend date is Tuesday, April 22nd. CVS Health's dividend payout ratio is currently 72.68%.

Insider Transactions at CVS Health

In other CVS Health news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael F. Mahoney bought 30,000 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the transaction, the director now owns 39,356 shares of the company's stock, valued at $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is currently owned by insiders.

Analysts Set New Price Targets

CVS has been the subject of several recent analyst reports. StockNews.com upgraded CVS Health from a "sell" rating to a "hold" rating in a research report on Thursday, February 13th. Leerink Partners raised shares of CVS Health from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Wells Fargo & Company lifted their price target on shares of CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. TD Cowen raised their target price on shares of CVS Health from $73.00 to $80.00 and gave the company a "buy" rating in a research report on Monday, November 25th. Finally, Argus set a $77.00 price target on shares of CVS Health in a report on Tuesday, February 18th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, CVS Health currently has an average rating of "Moderate Buy" and an average target price of $70.39.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.